CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A drug for advanced breast cancer prevents localized tumors from returning after surgery better than the current mainstay drug, according to a broad international study reported in Thursday's edition of the New England Journal of Medicine. Recurrence of such early cancer was reduced by one third in women who started on the gold standard treatment, tamoxifen, then switched after 2.5 years to the newer drug, exemestane, compared with those who took tamoxifen the entire time. The women switching to exemestane, a hormonal drug sold under the brand Aromasin, also suffered fewer serious side effects; they were 56% less likely to get cancer in the other breast and half as likely to develop unrelated cancer in other body areas. The research was partly funded by Pfizer Inc., the maker of Aromasin. The study, which included 4,742 postmenopausal women in 37 countries, focused on women with breast cancer in which the hormone estrogen fuels tumor growth--the type causing about 70% of the incidences of breast cancer. The results do not apply to premenopausal women or those with hard-to-treat breast cancer not driven by estrogen. Normally, early-stage breast cancer is treated by surgery to remove the tumor, plus radiation, if part of the breast is conserved. If tumor cells had spread to underarm lymph nodes, cell-killing cancer drugs often are given, particularly in the United States. Then, if the cancer is undetectable and also the type fueled by estrogen, women take daily tamoxifen pills for five years--to prevent any microscopic cancer cells lurking in the body from later triggering cancer in another spot. But cancer cells grow resistant to tamoxifen in many patients, sometimes within 12 months, and prolonged use can cause uterine cancer and dangerous blood clots. Lead researcher R.C. Coombes, professor of cancer medicine at Imperial College School of Medicine in London, predicted doctors will give exemestane to many women at high risk for recurrence, such as those whose breast cancer spreads to multiple lymph nodes.
From our Sponsors
Most Popular
Meet all 37 of the queer women in this season's WNBA
April 17 2024 11:24 AM
Here are the 15 gayest travel destinations in the world: report
March 26 2024 9:23 AM
After 20 years, and after tonight, Obama will no longer be the Democrats' top star
August 20 2024 12:28 PM
More Than 50 of Our Favorite LGBTQ+ Moms
May 12 2024 11:44 AM
Conjoined twins Lori Schappell and trans man George Schappell dead at 62
April 27 2024 6:13 PM